Evidence map›Paper›PMID 41283654›Full record

ArticleJournal of virology2025

HIV-2 glycoproteins upregulate microRNAs 25 and 93 to counter the MARCH1 antiviral effect in macrophages.

Robert Lodge, Dorota Kmiec, Frank Kirchhoff, Éric A Cohen

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Robert LodgeLaboratory of Human Retrovirology, Institut de recherches cliniques de Montréal (IRCM), Montreal, Quebec, Canada.ORCID 0000-0002-9908-0850
Dorota KmiecInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0001-7302-6015
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0002-7052-2360
Éric A CohenLaboratory of Human Retrovirology, Institut de recherches cliniques de Montréal (IRCM), Montreal, Quebec, Canada.ORCID 0000-0003-1269-3791

Funding

CIHR FDN-154324,HB2-164064
6 · The paper itself

Abstract

The membrane-associated E3 ubiquitin ligase MARCH1 restricts HIV-1 infectivity by decreasing the amount of cell surface Env glycoproteins and their incorporation into progeny virions. To circumvent this restriction, the HIV-1 accessory protein Vpu increases the levels of microRNAs 25 and 93 that target IMPORTANCE: Macrophage infection by primate lentiviruses (HIV-1, HIV-2, and SIV) is restricted by, among other host factors, the MARCH1 membrane-associated protein. HIV-1 circumvents the MARCH1 restriction by using its accessory protein Vpu, which induces the anti-MARCH1 microRNAs 25 and 93. HIV-2 has infected up to 2 million people so far, and SIV infection is indispensable for animal models of primate lentivirus pathogenesis. These two lentiviruses do not have a

Indexed as

HIV-2MacrophagesMicroRNAsUbiquitin-Protein LigasesAnimalsbeta CateninCell LineHIV-1HIV InfectionsHost-Pathogen InteractionsHumansSimian Immunodeficiency VirusTHP-1 CellsUp-RegulationViral Regulatory and Accessory ProteinsVirus Replicationbeta CateninMicroRNAsUbiquitin-Protein LigasesViral Regulatory and Accessory Proteinsbeta-cateninbeta-TrCPEnv glycoproteinHIV-2host restriction factormacrophageMARCH1microRNASIVTHP-1

Identifiers

PMID41283654
PMCPMC12724348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.